The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania.
The aim of the study was to evaluate the impact of a regional population-based genetic testing program on the incidence of ovarian cancer in West Pomerania. Between 1999 and 2010, a total of 37,552 women ages 35 to 70 were tested for three BRCA1 founder mutations at the outpatient genetics clinic of the Pomeranian Medical University in Szczecin, Poland. A total of 641 women were found to carry a mutation (1.7%) and of these, 220 had a prophylactic oophorectomy (34.3%). A total of 12 women had an occult cancer diagnosed at the time of prophylactic oophorectomy (5.5%). We estimate that 26 more ovarian cancers would have been diagnosed by January 2015 in the absence of these oophorectomies and that an additional 25 cancers will be prevented in the future (total 51). During this period, 1611 ovarian cancers were diagnosed in the region; therefore we estimate that approximately 1.6% of ovarian cancers were prevented between 1999 and 2015 by our genetic testing program. We conclude that the prophylactic oophorectomies performed between 1999 and 2010 as a result of widespread BRCA1 mutation testing have reduced the incidence of ovarian cancer in Pomerania by a small amount (about 1.6%), and that the impact of genetic testing will increase in the coming years.
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
J
J
Menkiszak
Women's College Research Institute, Women's College Hospital, Toronto, Canada.
V
V
Sopik
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
A
0000-0003-2784-7968
A
Chudecka-Głaz
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
W
W
Domagała
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
E
E
Urasińska
Department of Oncology and Chemotherapy, District Hospital, Koszalin, Poland.
H
H
Symonowicz
Department of Oncology and Chemotherapy, District Hospital, Koszalin, Poland.
E
E
Majdanik
NZOZ Zdunomed, Szczecin, Poland.
P
P
Waloszczyk
Histopathological Laboratory, Independent Public District Hospital, Szczecin, Poland.
K
K
Sycz
Department of Clinical Oncology, West Pomeranian Center of Oncology, Szczecin, Poland.
M
M
Świniarska
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
T
T
Huzarski
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
C
C
Cybulski
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
T
T
Debniak
Women's College Research Institute, Women's College Hospital, Toronto, Canada.
O
O
Oszurek
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
J
J
Lubinski
Women's College Research Institute, Women's College Hospital, Toronto, Canada.
S A
SA
Narod
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
J
J
Gronwald
D000328:Adult; D000368:Aged; D019313:BRCA1 Protein / Q000235:genetics*; D005260:Female; D018703:Founder Effect; D020022:Genetic Predisposition to Disease; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000453:epidemiology* / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy; D011044:Poland
D019313:BRCA1 Protein; C492913:BRCA1 protein, human
BRCA1; genetic testing; oophorectomy; ovarian cancer